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Background: Dementia with Lewy bodies (DLB) is a common form of dementia. The presence of Alzheimer’s
disease (AD) pathology modifies the clinical features of DLB, making it harder to distinguish DLB from AD
clinically during life. Clinical diagnostic criteria for DLB applied at presentation can fail to identify up to 50%
of cases. Our aim was to determine, in a series of patients with dementia in whom autopsy confirmation of
diagnosis was available, whether functional imaging of the nigrostriatal pathway improves the accuracy of
diagnosis compared with diagnosis by means of clinical criteria alone.
Methods: A single photon emission computed tomography (SPECT) scan was carried out with a dopaminergic
presynaptic ligand [123I]-2beta-carbometoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (FP-CIT;
ioflupane) on a group of patients with a clinical diagnosis of DLB or other dementia. An abnormal scan was
defined as one in which right and left posterior putamen binding, measured semiquantitatively, was more
than 2 SDs below the mean of the controls.
Results: Over a 10 year period it was possible to collect 20 patients who had been followed from the time of
first assessment and time of scan through to death and subsequent detailed neuropathological autopsy. Eight
patients fulfilled neuropathological diagnostic criteria for DLB. Nine patients had AD, mostly with coexisting
cerebrovascular disease. Three patients had other diagnoses. The sensitivity of an initial clinical diagnosis of
DLB was 75% and specificity was 42%. The sensitivity of the FP-CIT scan for the diagnosis of DLB was 88% and
specificity was 100%.
Conclusion: FP-CIT SPECT scans substantially enhanced the accuracy of diagnosis of DLB by comparison with
clinical criteria alone.
D
istinguishing patients with dementia with Lewy bodies
(DLB) from those with Alzheimer’s disease (AD) can be
challenging, in some cases even after repeated follow-up
observation. Imaging modalities which assess the integrity of
the nigrostriatal pathway have detected impaired function of
this pathway in patients with clinically diagnosed DLB but
preserved function in patients with clinically diagnosed AD.1–8
Such imaging is potentially of considerable value in supporting
a diagnosis of DLB. However, the accuracy of the clinical
diagnosis of DLB is imperfect,9 10 meaning that estimation of
the diagnostic accuracy of the imaging investigation needs to be
done against neuropathological findings.
We have been following a cohort of patients with dementia
whose initial dementia diagnosis was made on the basis of
standard clinical criteria (for AD,11 for DLB12). These patients
underwent a single photon emission computed tomography
(SPECT) scan using [123I]-2beta-carbometoxy-3beta-(4-iodo-
phenyl)-N-(3-fluoropropyl) nortropane (FP-CIT; ioflupane), a
ligand that binds to the presynaptic dopamine transporter,
demonstrating the integrity of the nigrostriatal projection
pathway. Scanning was undertaken at the time of presentation
to our service—that is, directly after the clinical diagnosis was
made. Autopsies are now available for 20 patients, enabling us
to report what abnormal FP-CIT scans actually equate to in
pathological terms. Furthermore, this autopsy series allows a
more robust assessment of the role of FP-CIT SPECT scanning
in the diagnosis of DLB than can be made using clinical
diagnoses only.
METHODS
Sixty-one clinically diagnosed patients and controls (17 AD, 27
DLB, 1 patient with cortico-basal degeneration (CBD) and 16
controls) were scanned with dopaminergic presynaptic ligand
FP-CIT SPECT between 1996 and 1999. All patients were then
prospectively followed-up. Of the original 45 patients with
dementia, 30 have died (67%) and in 22/30 cases the family
agreed to autopsy examination (73.3% autopsy rate). Here we
present the results of the first 20 patients with dementia in
whom comprehensive brain autopsy examination is available.
Detailed descriptions of the clinically diagnosed AD and DLB
patients, and the imaging results of the original clinical cohort,
have been published previously.5 At that time, autopsy results
were available for 10 of the cases and were reported briefly. In
the original cohort, patients with dementia were ascribed to
either the DLB or AD group on the basis of fulfilling the
Consensus DLB criteria12 or NINCDS-ADRDA criteria.11 Many of
the patients with DLB fulfilled both sets of criteria, and these
patients were classified as having DLB. In addition, in the series
reported here, we have included one further patient who was
diagnosed clinically as having CBD but nevertheless had a FP-
CIT SPECT scan and was followed prospectively and then
underwent autopsy. Sixteen healthy elderly controls (10 males;
Abbreviations: AD, Alzheimer’s disease; CBD, cortico-basal
degeneration; CVD, cerebrovascular disease; DLB, dementia with Lewy
bodies; LB, Lewy body; NFT, neurofibrillary tangle; PD, Parkinson’s
disease; PET, positron emission tomography; SMU, Strichman Medical
Unit; SPECT, single photon emission computed tomography
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6 females; mean age 67 years) were recruited from relatives and
partners of patients (mainly spouses). Their mean Unified
Parkinson’s Disease Rating Scale score was 2.2, mean Mini-
Mental State Examination score was 28.9 and mean Cambridge
Cognitive Examination score was 102.
FP-CIT SPECT scan
All subjects underwent scanning with a brain dedicated
scanner, the Strichman Medical Equipment 810 linked to a
Macintosh computer. The Strichman camera consists of 12
individual detectors, each equipped with a focusing collimator.
The transaxial resolution of this camera is 7.6 mm full width
half maximum and axial resolution is 12.5 mm. The measured
concentration of radioactivity was expressed as Strichman
Medical Units (SMUs; 1 SMU = 100 Bq/ml). Scanning took
place between 3 and 4 h after injection of FP-CIT (DaTSCAN)
(150–185 MBq). Usually 8–10 slices were acquired starting at
the cerebellum level upwards to include the basal ganglia. The
overall scanning time for each patient was 30–45 min.
Two patients were taking levodopa medication and three
patients were taking neuroleptic medication at the time of
scanning. One patient took sulpiride 200 mg at night and two
patients took olanzapine 5 mg/day. These medications were not
discontinued because they do not interfere with dopamine
transporter imaging.13–16
Semiquantitative analysis of scans
DCC, who was blinded to the clinical and autopsy diagnostic
status of all subjects, performed a semiquantitative analysis of
all scans. The images were reconstructed automatically. For the
analysis of striatal binding, the ratio of specific to non-specific
binding was calculated by summing the two adjacent trans-
verse slices that demonstrated the most intense striatal uptake.
Identical circular regions of interest were used to calculate the
average striatal (the caudate nucleus, the anterior and the
posterior putamen) to non-specific (the occipital cortex as a
region with little or no dopamine receptors) radioactivity ratios
for both hemispheres. The formula used was:
FP-CIT binding = STR/OCC
where STR is the mean radioactivity (in SMU) in the
striatum (caudate, anterior and posterior putamen) and OCC
is the mean radioactivity in the occipital cortex.
An abnormal scan, signifying a more likely diagnosis of DLB,
was defined as a scan with semiquantitative binding in the
posterior putamen (right and left), which was more than 2 SDs
below the mean of the controls. In the controls, the mean
values for left posterior putamen binding ratio and right
posterior putamen binding ratio were 4.43 and 4.44, respec-
tively. The mean for left plus right posterior putamen binding
ratio was 8.87 (SD 1.46). Thus the mean minus 2 SDs was 5.95
(fig 1). We also present the results based on defining an
abnormal scan as having posterior putamen binding on just one
side (either right or left) more than 2 SDs below the mean of
the controls (ie, ,2.91).
Visual rating of scans
As a separate exercise, all scans were presented randomly and
assessed visually by three independent raters (DCC, ZW and
RWHW) experienced in assessing FP-CIT scans, who were
blinded to the clinical and autopsy diagnoses. Scans were
scored as follows: normal uptake in all regions (right and left
caudate and right and left putamen) = 0; slight reduction in
uptake in any of the four regions = 1; and significant reduction
in uptake in any of the four regions = 2. Subsequently, for all
statistical analyses, scans with scores of 0 or 1 were combined
into a ‘‘normal’’ group and scans with a score 2 were declared
‘‘abnormal’’.
Neuropathological examination
Detailed neuropathological examination was performed in
Newcastle by RP, PI and EJ.
Brain areas sampled
At autopsy, the left cerebral and cerebellar hemispheres were
dissected and snap frozen for neurochemical examination. The
right half of the brain was fixed in formalin, coronally sliced at
7 mm intervals, and cortical, subcortical and brainstem areas
were sampled and embedded in paraffin to establish the
neuropathological diagnosis. The brain areas sampled included
the entorhinal cortex at the level of the uncus; hippocampus
and medial temporal cortex at the level of the geniculate bodies;
anterior cingulate cortex; and cerebral neocortex and adjoining
deep white matter at the pre-frontal, mid-frontal, posterior
frontal, posterior lateral parietal, lateral temporal (at the level
of the geniculate bodies) and the posterior occipital levels. The
subcortical nuclei sampled included the amygdala, striatum,
globus pallidus, thalamus and subthalamic nucleus. In the
cerebellum, the vermis, medial and lateral cerebellar hemi-
sphere and dentate nucleus were sampled. The brainstem
nuclei sampled included the substantia nigra at the level of the
red nucleus and the decussation of the cerebellar peduncle,
pedunculo-pontine nucleus, dorsal raphe nucleus, locus
Figure 1 Total (right and left) posterior putamen radioactivity ratios for
cases of dementia with Lewy bodies (DLB) and other dementia cases. The
horizontal line on the graph marks the value (5.95) for 2 SDs below the
mean of the total posterior putamen binding ratios of the controls.
Table 1 Clinical characteristics of the neuropathologically
diagnosed patients with and without dementia with Lewy
bodies
Characteristic
DLB (%)
(n = 8)
Non-DLB (%)
(n = 12)
Positive family history of dementia 2 (25) 4 (33)
Past psychiatric history 0 (0) 2 (17)
Acute confusional states 2 (25) 0 (0)
Rigidity 5 (63) 4 (33)
Akinesia/bradykinesia 5 (63) 5 (42)
Tremor 4 (50) 8 (67)
Fluctuating course of illness 6 (75) 7 (58)
Visual hallucinations
Once only 2 (25) 1 (8)
Persistent 4 (50) 5 (42)
DLB, dementia with Lewy bodies.
There were no significant differences between the DLB and non-DLB groups.
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coeruleus, pontine nuclei, dorsal nucleus of vagus, reticular
formation and inferior olive.
Neurohistology
Paraffin sections (6 mm) from the cortical, subcortical and
brainstem areas were examined using standard neuropatholo-
gical stains, including haematoxylin and eosin for general
histology, cresyl fast violet for neuronal population density,
Loyez for myelin, Gallyas or methenamine silver stains and AT8
(monoclonal antibodies to the tau protein phosphorylated at
Ser-202; 90206 (BR-003) Innogenetics antibodies from
AutogenBioclear UK Ltd, Calne, Wiltshire, UK) for neuritic
plaques, Gallyas for neurofibrillary tangles (NFTs) and ghost
tangles, AT8 for pre-tangles and NFTs, a-synuclein (mono-
clonal antibodies recognising an epitope of the protein at AA 1–
60; NCL-ASYN Novocastra antibodies from VisionBiosystems
Europe Ltd, Newcastle upon Tyne, UK) for Lewy bodies (LBs),
pre-LBs and neurites, ubiquitin (polyclonal antibodies Z0458
from Dako UK Ltd, Ely, Cambridgeshire, UK) for LBs in some
cases and bA4 antibodies (monoclonal M0872 from Dako UK
Ltd) for amyloid angiopathy and diffuse and plaque associated
amyloid.
Neuropathological diagnostic criteria
The neuropathological diagnostic criteria employed for AD
included the following: CERAD (Consortium to Establish a
Registry for Alzheimer’s Disease) score and diagnosis,17 Braak
stage18and NIA-RI (National Institute on Aging and Reagan
Institute) AD diagnosis.19 In addition, based on experience at
Newcastle,20 NFTs were counted in the temporal, frontal,
parietal and occipital neocortex and their densities (number
per mm2) were used to stage the neocortical NFT pathology as
follows: none = no NFTs in the neocortex; not significant =
fewer than 4 NFTs per mm2 in each of the four lobes; moderate
= fewer than 4 NFTs per mm2 in one or more lobes but mean
density from all the four lobes of more than 4 NFTs per mm2;
significant = more than 4 NFTs per mm2 in each of the four
lobes.
The neuropathological diagnostic criteria employed for DLB
were those recommended by the Third report of the DLB
Consortium.21
Statistics
Data were analysed using SPSS/PC+ version 12.0.1 (Statistical
Package for Social Sciences). Taking the autopsy diagnosis to be
the ‘‘true’’ or ‘‘gold standard’’ diagnosis, we calculated the
sensitivity and specificity of FP-CIT SPECT and the sensitivity
and specificity of the Consensus DLB criteria (1996) applied at
the initial clinical assessment for making the diagnosis of DLB.
Table 2 Demographic characteristics and test scores of
neuropathologically diagnosed patients with and without
dementia with Lewy bodies
Characteristic
DLB
(n = 8)
Non-DLB
(n = 12)
Sex ratio (M:F) 3:5 3:9
Age at onset of dementia (y) 73.3 (9) 73.2 (10)
Age at time of FP-CIT (y) 76.5 (9) 77.8 (9)
Time from scan to death (months) 34 (22) 34 (26)
Years of education 9.5 (1.4) 10.4 (1.9)
H&Y stage 1.9 (1.5) 1.4 (1.5)
UPDRS score 18.1 (13.8) 13.0 (12.7)
MMSE 17 (5.6) 16.6 (8.8)
CAMCOG 60 (21) 41 (27)
CAPE 9.4 (7) 12.3 (9)
GDS 3.9 (3) 3.3 (2)
CDR 1.4 (0.9) 1.7 (0.9)
Behave-AD 10.3 (7) 10.3 (8)
Behave-AD, behavioural pathology in Alzheimer’s disease; CAMCOG,
Cambridge Cognitive Examination; CAPE, Clifton Assessment Procedure for
the Elderly; CDR, Clinical Dementia Rating; DLB, dementia with Lewy bodies;
GDS, Geriatric Depression Scale; H&Y stage, Hoehn and Yahr stage;
MMSE, Mini-Mental State Examination; UPDRS, Unified Parkinson’s Disease
Rating Scale (motor section).
Values are mean (SD).
There were no significant differences between the DLB and non-DLB groups.
Table 3 Initial clinical, imaging and autopsy diagnosis
Case
No
Clinical
diagnosis
No of core
features of
DLB
Visual
rating
diagnosis
Semiquantitative
diagnosis
Neuropathological
diagnosis
1 AD 0 Abn Abn DLB+AD
2 DLB 3 Abn Abn DLB
3 DLB 2 N Abn DLB
4 DLB 2 Abn Abn DLB+AD+CVD
5 CBD 1 Abn N DLB+AD
6 DLB 2 Abn Abn DLB
7 DLB 2 Abn Abn DLB+CVD
8 DLB 3 Abn Abn DLB
9 AD 0 N N AD+CVD
10 AD 0 N N AD+CVD+metastatic carcinoma
11 DLB 2 Abn N AD+CVD
12 DLB 2 N N AD
13 DLB 2 N N CBD
14 DLB 2 N N AD
15 AD 1 N N Unspecified pathology
16 AD 0 N N AD +CVD
17 DLB 1 Abn N FTLD
18 DLB 2 N N AD
19 DLB 2 N N AD+CVD
20 AD 0 N N AD+CVD
Abn, abnormal scan; AD, Alzheimer’s disease; CBD, cortico-basal degeneration; CVD, cerebrovascular disease; DLB,
dementia with Lewy bodies; FTLD, fronto-temporal lobar degeneration; N, normal scan.
In the visual rating there was complete agreement between all three raters for 15 cases. In the remaining five cases there
was a 2:1 split. In two of these cases the dissent related to scores of 0 or 1, therefore having no effect on the assignment
of the scan as normal or abnormal. The three cases where disagreement potentially affected the assignment of the scan
were case Nos 1, 7 and 12.
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Ethics approval
Ethics approval was obtained for the imaging study, and
separate ethics approval was obtained from West Essex Health
Authority Ethics Committee for the autopsy follow-up.
RESULTS
Patient demographic characteristics and clinical features at
presentation are shown in tables 1 and 2. There was no
significant difference between the neuropathologically diag-
nosed DLB and non-DLB groups with regard to any of the
demographic or clinical characteristics, including the frequency
of parkinsonian signs, visual hallucinations and clinical
fluctuation. One patient with neuropathologically diagnosed
DLB and two neuropathologically diagnosed AD patients were
receiving neuroleptic medication. One neuropathologically
diagnosed CBD patient (clinical diagnosis of DLB) was treated
with antiparkinsonian medication, as was one clinically and
neuropathologically diagnosed DLB patient. The mean time
from clinical diagnosis and FP-CIT scan to autopsy was
34 months (range 6–94).
Patients with a neuropathological diagnosis of DLB had
significantly lower radioactivity uptake than non-DLB patients
in the caudate nucleus (p,0.01) and in the anterior (p,0.05)
and posterior putamen (p,0.0001).
Clinical diagnoses, semiquantitative imaging assessments
(using right and left posterior putamen binding), visually rated
imaging assessments and neuropathological diagnoses are
displayed in table 3. More detailed neuropathological features
and diagnostic criteria are summarised in table 4.
The sensitivity of an initial clinical diagnosis of DLB was 75%
and specificity was 42%. The sensitivity of visually rated scans
for making a diagnosis of DLB was 88% and specificity was
83%. The sensitivity of semiquantitatively analysed scans was
88% and specificity was 100%. Using the alternative semi-
quantitative method where an abnormal scan only needed low
posterior putamen binding on one side, sensitivity was 100%
and specificity was 92% (case No 19, PM diagnosis AD with
CVD, had an abnormal scan).
During follow-up of the patients, the clinical diagnoses were
changed in three cases; in three further cases with initial
diagnoses of DLB the diagnosis was modified from probable to
possible. The sensitivity and specificity of the clinical diagnosis
of DLB became 88% and 58%, respectively, but it should be
pointed out that these changes in diagnosis were made not just
on the basis of further clinical observation of the patients but in
the knowledge of the results of their FP-CIT scans, although at
the time we did not know how reliable the FP-CIT scans might
be.
Table 4 Neuropathological diagnosis and diagnostic criteria
Case
No
EPF
at time
of scan
Clinical
diagnosis
Neuropathological
diagnosis
Braak
stage
Neocortical
NFT stage*
CERAD
score
AD
diagnosis
by CERAD
criteria
AD diagnosis
by NIA-RI
criteria
Category of
LB pathology
by Consensus
criteria - 2003
Probability:
dementia due
to LB pathology
by Consensus
criteria - 2005
1 – AD Mixed DLB, AD and HiScl 5 Moderate Moderate Probable NAp Neocortical Intermediate
2 + DLB DLB 0 None None Normal-1c None Neocortical High
3 + DLB DLB 3 None None Normal-1c NAp Neocortical High
4 + DLB Mixed DLB and AD in MTL
and SVD
4 NS Moderate Probable Intermediate Neocortical –
severe
High
5 + CBD Mixed DLB and AD 6 Significant Frequent Definite High likelihood Neocortical Intermediate
6 – DLB DLB 2 None Sparse Possible Low likelihood Neocortical High
7 + DLB DLB and focal vascular
pathology
2 None None Normal-1c None Neocortical High
8 + DLB DLB 1 NS none Normal-1c NAp Neocortical –
severe
High
9 – AD AD and focal SVD and
severe Purkinje cell loss
6 Significant Frequent Definite High likelihood None None
10 – AD AD and focal vasculopathy
and occipital microinfarct
5 Moderate Frequent Definite High likelihood None None
11 + DLB Mixed AD and CAA and
haemorrhagic infarcts
5 Moderate Frequent Definite High likelihood None None
12 – DLB AD and mild SVD 6 Significant Frequent Definite High likelihood None None
13 + DLB CBD variant - non-tau
balloon cell degeneration
and subcortical tangle
disease
2 None Moderate Probable NAp None None
14 + DLB AD 5 ? Frequent Definite High likelihood None None
15 – AD Minimal neuropathology:
focal SVD and mild LB
pathology and focal
cortical lesions
1 None None Normal-1c NAp Brainstem Low
16 – AD AD and HiScl and focal
SVD
6 Significant Frequent Definite High likelihood None None
17 + DLB FTLD (DLDH) and HiScl and
nigral degeneration
0 None None Normal-1c None None None
18 – DLB AD 5 Significant Frequent Definite High likelihood None None
19 + DLB Mixed AD and CAA and
focal vascular pathology
6 Significant Moderate Probable NAp None None
20 – AD Mixed AD and SVD and
multiple microinfarcts
5 Moderate Frequent Definite High likelihood None None
AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy; CBD, cortico-basal degeneration; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease;
DLDH, dementia lacking distinctive histology; DLB, dementia with Lewy bodies; EPF, extrapyramidal features; FTLD, frontotemporal lobar degeneration; HiScl,
hippocampal sclerosis; LB, Lewy body; MTL, medial temporal lobe; NAp, not applicable; NFT, neurofibrillary tangle; NIA-RI, National Institute on Aging and Reagan
Institute; NS, not significant; SVD, small vessel disease.
*Newcastle and Helsinki criteria.
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DISCUSSION
The results of this study indicate that FP-CIT SPET scans have
good sensitivity and very good specificity for diagnosing DLB.
In this series, ‘‘dementia not otherwise specified plus abnormal
scan’’ performed considerably better than clinical criteria alone
as a means of making the diagnosis of DLB. The FP-CIT
semiquantitative measurements performed better than might
be anticipated from previous clinico-imaging studies.5 6 In our
clinical study,5 sensitivity was 52% and specificity was 94%
(results not shown in the original paper). In a similar study,6
sensitivity was 78% and specificity was 94%. The reason for the
better results in our autopsy study is that studies based solely
on clinical diagnosis will misclassify a proportion of the
patients into incorrect diagnostic categories which leads to a
mismatch between scan result and diagnosis.
Compared with previous retrospective and prospective
clinicopathological studies,22 the sensitivity and particularly
the specificity of our clinical diagnosis was poor. There are
several possible explanations for this. The clinical diagnosis was
made using the Consensus criteria but usually by only one
clinician and was not a diagnosis made by the agreement of a
panel of three expert clinicians, as was done, for instance, in a
Newcastle cohort.9 The clinical diagnosis was made at baseline,
before patients were scanned. At follow-up, the clinical
diagnosis sometimes changed, but for the purpose of this study
we used only the baseline diagnosis for analysis of results. The
reason for this was that we were particularly interested to
gauge how well the FP-CIT imaging technique performed in the
initial stages of assessment for dementia. A high proportion of
the non-DLB patients were thought to have symptoms and
signs characteristic of DLB patients, namely persistent halluci-
nations, fluctuations and parkinsonian symptoms. On the other
hand, one of the DLB patients did not have any core features of
DLB at baseline (case No 1) and two DLB patients did not have
any parkinsonian symptoms (case Nos 1 and 6). In cases such
as these, the scan could be particularly helpful. A high
proportion of the non-DLB cases had one or more core features
of DLB (see tables 2 and 3). This illustrates the difficulty that
clinicians face when making a diagnosis of DLB as all the
characteristic features of DLB can be present in possible AD
cases.
The majority of the non-DLB cases had AD and it might
appear surprising that there was no significant difference
between the DLB and non-DLB groups with regard to
hallucinations and signs of parkinsonism. We believe there
are three explanations. Firstly, this was a small series. Secondly,
the non-DLB group included a case of CBD and a case of FTD,
both of which, unsurprisingly, had rigidity. Thirdly, many of
the cases were recruited from a diagnostic memory clinic to
which they had been referred because of diagnostic difficulty,
so they were possibly not typical cases. This may also account
for the relatively low accuracy of the clinical diagnosis of AD in
this series.
In this study, our cut-off between normal and abnormal
scans was 2 SDs below the mean of the controls, which is
slightly more stringent than the 1.5 SD used by O’Brien and
colleagues.6 In general, a less stringent cut-off would be
expected to increase sensitivity but reduce specificity.
Case No 5 was the only DLB patient whose FP-CIT scan
(semiquantitative assessment) was in the normal range. The
patient was relatively young, with onset of symptoms at
55 years. The presenting symptom was strikingly unilateral,
an inability to use the right hand, with apraxia and myoclonus,
leading to an initial clinical diagnosis (by RWHW) of CBD. She
then developed a rapidly evolving amnesia. Putaminal FP-CIT
binding was clearly abnormal on the left side (visually rated as
abnormal), but normal on the right side, such that the right
plus left putamen binding ratio was within the normal range.
At autopsy (note that the right but not the left sided basal
ganglia were examined histologically—see methods), there was
only mild neuron loss in the substantia nigra with mild a-
synuclein pathology, and widespread tangle/neuritic pathology
in both the putamen and caudate revealed by AT8 tau
immunohistochemistry and Gallyas silver staining. The autopsy
did show diffuse neocortical LB-type pathology, and so the
patient can be classified as a DLB case, but there was severe AD
pathology such that the retrospective likelihood of a clinical
DLB syndrome was ‘‘intermediate’’ according to the DLB
consortium’s third report.21 Thus the semiquantitatively
assessed scan result represents a false negative. (Using the
alternative semiquantitative method, based on a unilateral
analysis, the scan was abnormal.)
Assessing scans on the basis of abnormality on one side
(whichever side is more abnormal) increased sensitivity but
reduced specificity. The typical abnormality in DLB is bilateral
loss of binding, mainly in the putamen but also in the caudate
nuclei. Generally there is less asymmetry than in Parkinson’s
disease (PD).23 Case No 11 had strictly unilateral loss of
putamen binding and so had to be judged visually as abnormal
for the purpose of our study even though the appearances were
not typical of DLB. The semiquantitative bilateral putamen
binding ratio was in the normal range. Autopsy showed
extensive vascular disease, which involved the substantia nigra
and putamen, accounting for the scan abnormality. Ideally, FP-
CIT scans should always be evaluated with good quality
structural imaging available.
We are aware of reports from only two other groups which
have correlated functional imaging and autopsy findings in
DLB.7 24 In one,24 positron emission tomography (PET) scans of
patients with an autopsy diagnosis of DLB or AD were
examined retrospectively. Glucose hypometabolism of the
occipital cortex, particularly of the primary visual cortex,
distinguished DLB from AD with 90% sensitivity and 80%
specificity. Strictly speaking, none of the ‘‘DLB’’ cases had a
clinical diagnosis of DLB but rather had PD with dementia
(three cases), and the rest of the patients had a clinical
diagnosis of AD. On this evidence, FP-CIT has comparable
sensitivity but better specificity than occipital cortex metabo-
lism measured by PET. The other study,7 using a functional
imaging technique similar to FP-CIT SPECT (dihydrotetrabe-
nazine PET), reported just three cases with autopsy diagnoses
of DLB (two cases) and AD (one case), with scan abnormalities
in keeping with the autopsy diagnoses.
An abnormal FP-CIT SPECT scan, as defined in this study,
equates to a bilateral lesion of the dopaminergic neurons
projecting from the substantia nigra to the striatum, specifically
to the putamen. Clearly the commonest cause of this is
idiopathic PD. The same abnormality is to be expected, and is
indeed found, in PD with dementia.6 An abnormal scan is not
specific for LB pathology. How reliably it identifies patients
with DLB will depend on the population of patients tested. For
instance, PD and multiple systems atrophy cannot be distin-
guished by FP-CIT SPECT. Ordinarily, multiple systems atrophy
is not characterised by dementia and so will not be a source of
false positives. There are however some (mainly rare) neuro-
logical disorders which might be expected to give ‘‘false
positive’’ results, reducing the specificity of the test. These
might include vascular parkinsonism with dementia, and other
forms of parkinsonism with dementia such as CBD, progressive
supranuclear palsy, frontotemporal dementia with parkinson-
ism linked to chromosome 17 and Creutzfeldt–Jakob disease. In
some of these conditions the main striatal dopaminergic lesion
is however postsynaptic rather than presynaptic. Multiple
pathologies represent another important possible cause of false
1180 Walker, Jaros, Walker, et al
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positive scan results. PD is common. Incidental or presympto-
matic nigral LB disease at autopsy is also not uncommon. It
must be possible for patients to have, for instance, AD and also
have PD or incidental nigral LB disease without having diffuse
LB disease. Autopsies of such cases have been reported.25 In
such cases, FP-CIT binding in the caudate would be expected to
be relatively preserved23 but both visual and semiquantitative
rating of putaminal binding would give an abnormal scan
result. Widespread use of FP-CIT scans in very large numbers of
patients with unselected dementia would be expected to
generate a number of false positive results. It goes without
saying that scanning is no substitute for careful clinical
assessment of patients.
What about false negatives? The rationale of the abnormal
scan as a test result which supports a diagnosis of DLB is based
on the premise that patients with dementia caused by cortical
LB pathology will have significant nigrostriatal pathology even
if clinical parkinsonism cannot be detected. If there was a group
of patients who had extensive cortical LB pathology without
nigrostriatal involvement, they would have false negative FP-
CIT scans. Isolated cases of cortical LB pathology without
brainstem LB pathology have been described26 but are rare. The
majority of reports emphasise that cases with cortical LB
pathology invariably also have substantia nigra LB pathol-
ogy.12 27 28 It has been suggested that in cases of DLB with
cerebral cortex predominant LB pathology, the progression of
LB pathology is from the cerebrum to the brainstem.28 If that is
correct it might be possible for such individuals to have
dementia due to cortical LB pathology at a time when their
substantia nigra LB pathology was insufficiently advanced to
give rise to a positive FP-CIT scan.
The above reservations notwithstanding, our conclusion from
this study is that FP-CIT SPECT scanning performed consider-
ably better than clinical criteria as a means of supporting the
diagnosis of DLB in patients with dementia. It correlated very
well with the presence of LB pathology at autopsy, even with a
gap of nearly 3 years, on average, between scan and autopsy
(see table 2). It clearly supports the recent change made in the
Revised clinical criteria for the diagnosis of DLB21 which now
includes ‘‘low dopamine transporter uptake in the basal ganglia
demonstrated by SPECT imaging’’ as a ‘‘suggestive feature’’ for
DLB.
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